Russia launched Covid-19 Vaccine ‘Sputnik-V’: Here’s everything you need to know

Team Udayavani, Aug 14, 2020, 12:36 PM IST

Russia became the first country to grant regulatory approval to a Covid-19 vaccine, dubbed “Sputnik V” Chief researcher Elena Smolyarchuk, who heads the Center for Clinical Research on Medications at Sechenov University said that the human trials for the vaccine have been completed at the university and they will be discharged soon

Russian President Putin’s daughter has already been given the jab of Russia’s Covid-19 vaccine. According to ET, Russia’s trials allowed for the civil use and inoculation of the vaccine while simultaneously conducting late-stage trials. Epidemiologists and medical experts, including the WHO believe that such a move can put people at risk.

How will the vaccine work?

Based on the DNA of a SARS-CoV-2 type adenovirus, it uses the weakened virus to deliver small parts of pathogen and stimulate and immune response. The vaccine would be administered in two shots, 21 days apart

Clinical trial

The Quint reports state that clinical trials of the vaccine began on 18 June with 38 volunteers who developed immunity. Another trial was started on 20 July. The trials were conducted at 7 sites across the country.

Who will receive the vaccine first?

Reports suggests that doctors and teachers would be among the first groups to vaccinated. Also, Russia’s elite has been given the experimental  vaccine. Russia has received several foreign requests for 1 billion doses.

Kirill Dmitriev, head of the RIFF said that more than 20 countries have shown interest in the Russia’s vaccine.


Production of the vaccine

Sources claim that Russia’s first potential vaccine will be approved by regulators this month and production is all set to begin September. Also, reports suggest that on 1 August, Health Minister Murashko said that Russian plans on starting a mass vaccination campaign against the novel coronavirus in October.

Skepticism about the Russian Vaccine?

However, World Health Organisation (WHO) has said they don’t have enough information about the Russian vaccine to evaluate its potency against Covid-19 pandemic. According to Indian Express, AIIMS director Randeep Guleria said, “We will have to see critically whether it is safe and effective. There should not be any side effects of the vaccine and it should provide good immunity and protection. India has the capacity for mass production of vaccine.”

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

“Subject to condition ….”: K’taka govt lifts weekend curfew

Karnataka govt opposes TN’s water project at Hogenakkal

Do you see any other face: Priyanka on Cong’s CM candidate in UP polls

Netaji’s grand statue to be installed at India Gate: PM Modi

Bommai thanks PM for advance installment of tax devolution of Rs 3,467.62 cr

Andhra woman walks into police station with husband’s severed head, confesses to murder

Mangaluru: Couple arrested for honey-trapping astrologer

Related Articles More

M’luru: Rise in Covid; 5 more schools closed in DK

Delhi govt caps RT-PCR price at pvt hospitals, labs at Rs 300

COVID-19 health emergency could be over this year, WHO says

Centre flags decline in Covid testing, asks states to enhance it

Go for test for TB, other conditions if cough persists for more than 2-3 weeks: Revised clinical guidance for Covid patients


Amar Jawan Jyoti Extinguished

DK Shivakumar statement about covid rules break by BJP

An injured monkey falling from an electrical wire in Dandeli’s bypass

video of professor principal brawl in madhya pradesh college

NEWS BULLETIN 20-01-2022

Latest Additions

“Subject to condition ….”: K’taka govt lifts weekend curfew

Karnataka govt opposes TN’s water project at Hogenakkal

Navy personnel killed on INS Ranvir cremated in HP with full state honours

Cong didn’t respond to Sena’s pre-poll alliance plan in Goa, it is to be blamed if BJP wins: Raut

Four people ‘associated’ with Bajrang Dal held for murder of Muslim youth in Karnataka

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.